Drug Patents owned by Bayer Hlthcare

1. Drug name - ADEMPAS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7173037 BAYER HLTHCARE Carbamate-substituted pyrazolopyridines
Dec, 2026

(4 years from now)

US11203593 BAYER HLTHCARE Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
Feb, 2034

(11 years from now)

US10662188 BAYER HLTHCARE Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate
Feb, 2034

(11 years from now)

CN105102457A BAYER HLTHCARE Forms Of Methyl {4.6-Diamino-2-[1-(2-Fluorobenzyl)-1H- Pyrazolo [3.4-B] Pyridino-3-Yl]Pyrimidino-5-Yl} Methylcarbamate
Jun, 2020

(2 years ago)

CN1665811A BAYER HLTHCARE Carbamate-Substituted Pyrazolopyridine Compound
Apr, 2023

(6 months from now)

CN1330649C BAYER HLTHCARE Carbamate-Substituted Pyrazolopyridine Compound
Apr, 2023

(6 months from now)

IN313139B BAYER HLTHCARE Carbamate Substituted Pyrazolopyridines
Apr, 2023

(6 months from now)

IN200403374P1 BAYER HLTHCARE Carbamate-Substituted Pyrazolopyridines
Apr, 2023

(6 months from now)

EP1506193B1 BAYER HLTHCARE Carbamate-Substituted Pyrazolopyridines
Apr, 2028

(5 years from now)

EP1506193A1 BAYER HLTHCARE Carbamate-Substituted Pyrazolopyridines
Apr, 2028

(5 years from now)

EP2958914B1 BAYER HLTHCARE Forms Of Methyl {4,6-Diamino-2-[1-(2-Fluorobenzyl)-1H-Pyrazolo[3,4-B]Pyridino-3-Yl]Pyrimidino-5-Yl}Methyl Carbamate
Feb, 2034

(11 years from now)

EP2958914A1 BAYER HLTHCARE Forms Of Methyl {4,6-Diamino-2-[1-(2-Fluorobenzyl)-1H-Pyrazolo[3,4-B]Pyridino-3-Yl]Pyrimidino-5-Yl}Methyl Carbamate
Feb, 2034

(11 years from now)

Drugs and Companies using RIOCIGUAT ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
0.5MG TABLET;ORAL Prescription
1MG TABLET;ORAL Prescription
1.5MG TABLET;ORAL Prescription
2MG TABLET;ORAL Prescription
2.5MG TABLET;ORAL Prescription

2. Drug name - ANGELIQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8906890 BAYER HLTHCARE Very low-dosed solid oral dosage forms for HRT Oct, 2031

(9 years from now)

More Information on Dosage
Strength Dosage Availability
0.25MG;0.5MG TABLET;ORAL Prescription
0.5MG;1MG TABLET;ORAL Prescription

3. Drug name - ASTEPRO ALLERGY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518919 BAYER HLTHCARE Compositions comprising azelastine and methods of use thereof Nov, 2025

(3 years from now)

US9919050 BAYER HLTHCARE Compositions comprising azelastine Nov, 2025

(3 years from now)

US8071073 BAYER HLTHCARE Compositions comprising azelastine and methods of use thereof Jun, 2028

(5 years from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Treatment: Otc use: allergy symptom reliever; temporary relief of these symptoms due to hay fever or other upper respiratory allergies: nasal congestion, runny nose, sneezing and itchy nose

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.2055MG/SPRAY SPRAY, METERED;NASAL Over the counter

4. Drug name - BEYAZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6441168 BAYER HLTHCARE Stable crystalline salts of 5-methyltetrahydrofolic acid
Jul, 2022

(2 months ago)

CN1154648C BAYER HLTHCARE 5-Stable Crystalline Calcium Salt Of Methyl Tetrahydrofolate And Preparation Method And Use Thereof
Apr, 2020

(2 years ago)

CN1277197A BAYER HLTHCARE Stable Crystalline Salt Of 5-Methyl Tetrahydrofolic Acid
Apr, 2020

(2 years ago)

EP1044975B1 BAYER HLTHCARE Stable Crystalline Salt Of 5-Methyl-(6S)-Tetrahydrofolic Acid
Apr, 2020

(2 years ago)

EP2189459A1 BAYER HLTHCARE Stable Crystalline Salt Of 5-Methyl-(6S)-Tetrahydrofolic Acid
Apr, 2020

(2 years ago)

EP2194057B1 BAYER HLTHCARE Stable Crystalline Calcium Salt Of 5-Methyl-(6S)-Tetrahydrofolic Acid
Apr, 2020

(2 years ago)

EP1044975A1 BAYER HLTHCARE Stable Crystalline Salt Of 5-Methyl-(6S)-Tetrahydrofolic Acid
Apr, 2020

(2 years ago)

EP2192120B1 BAYER HLTHCARE Stable Crystalline Calcium Salt Of 5-Methyl-(6S)-Tetrahydrofolic Acid
Apr, 2020

(2 years ago)

EP2189459B1 BAYER HLTHCARE Stable Crystalline Salt Of 5-Methyl-(6S)-Tetrahydrofolic Acid
Apr, 2020

(2 years ago)

EP2192120A1 BAYER HLTHCARE Stable Crystalline Calcium Salt Of 5-Methyl-(6S)-Tetrahydrofolic Acid
Apr, 2020

(2 years ago)

EP2194057A1 BAYER HLTHCARE Stable Crystalline Calcium Salt Of 5-Methyl-(6S)-Tetrahydrofolic Acid
Apr, 2020

(2 years ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617597 BAYER HLTHCARE Pharmaceutical composition containing a tetrahydrofolic acid Feb, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
3MG,N/A;0.02MG,N/A;0.451MG,0.451MG TABLET;ORAL Prescription

5. Drug name - KERENDIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8436180 BAYER HLTHCARE Substituted-4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
Apr, 2029

(6 years from now)

CN101641352B BAYER HLTHCARE Substituted 4-Aryl-1,4-Dihydro-1,6-Naphthyridinamides And Use Thereof
Feb, 2028

(5 years from now)

CN101641352A BAYER HLTHCARE Substituted 4-Aryl-1,4-Dihydro-1,6-Naphthyridinamides And Use Thereof
Feb, 2028

(5 years from now)

IN200904992P1 BAYER HLTHCARE Substituted 4-Aryl-1,4-Dihydro-1,6-Naphthyridine Amides And Their Use
Feb, 2028

(5 years from now)

IN300241B BAYER HLTHCARE Substituted 4-Aryl-1, 4-Dihydro-1, 6-Naphthyridine Compound Of Formula (I)
Feb, 2028

(5 years from now)

EP2132206B1 BAYER HLTHCARE Substituted 4-Aryl-1,4-Dihydro-1,6-Naphthyridinamides And Use Thereof
Feb, 2028

(5 years from now)

EP2132206A2 BAYER HLTHCARE Substituted 4-Aryl-1,4-Dihydro-1,6-Naphthyridinamides And Use Thereof
Feb, 2028

(5 years from now)

Drugs and Companies using FINERENONE ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription

6. Drug name - KYLEENA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7252839 BAYER HLTHCARE Delivery system and a manufacturing process of a delivery system Nov, 2023

(1 year, 1 month from now)

US10561524 BAYER HLTHCARE Inserter Sep, 2029

(6 years from now)

US9615965 BAYER HLTHCARE Inserter Sep, 2029

(6 years from now)

US10987244 BAYER HLTHCARE Inserter Apr, 2031

(8 years from now)

US9668912 BAYER HLTHCARE Inserter Apr, 2031

(8 years from now)

Drugs and Companies using LEVONORGESTREL ingredient

Treatment: A method of positioning an intrauterine system (ius) by determining a depth of the uterus, holding an inserter handle with one hand, inserting the ius into the uterus, and retracting a slider on the handle to release the ius into the uterus; A method of positioning an intrauterine system by holding an inserter handle with one hand, advancing the inserter through the cervix and into the uterus, and retracting a slider on the handle to release the intrauterine system

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

More Information on Dosage
Strength Dosage Availability
19.5MG INTRAUTERINE DEVICE;INTRAUTERINE Prescription

7. Drug name - LEVITRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8841446 BAYER HLTHCARE Medicaments containing vardenafil hydrochloride trihydrate Jul, 2023

(9 months from now)

US8273876 BAYER HLTHCARE Medicaments containing vardenafil hydrochloride trihydrate Jul, 2027

(4 years from now)

Drugs and Companies using VARDENAFIL HYDROCHLORIDE ingredient

Treatment: Treatement of erectiile dysfunction by administering a film-coated tablet

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 2.5MG BASE TABLET;ORAL Discontinued
EQ 5MG BASE TABLET;ORAL Discontinued
EQ 10MG BASE TABLET;ORAL Discontinued
EQ 20MG BASE TABLET;ORAL Discontinued

8. Drug name - MIRENA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561524 BAYER HLTHCARE Inserter Sep, 2029

(6 years from now)

US9615965 BAYER HLTHCARE Inserter Sep, 2029

(6 years from now)

US10987244 BAYER HLTHCARE Inserter Apr, 2031

(8 years from now)

US9668912 BAYER HLTHCARE Inserter Apr, 2031

(8 years from now)

Drugs and Companies using LEVONORGESTREL ingredient

Treatment: A method of positioning an intrauterine system (ius) by determining a depth of the uterus, holding an inserter handle with one hand, inserting the ius into the uterus, and retracting a slider on the handle to release the ius into the uterus; A method of positioning an intrauterine system by holding an inserter handle with one hand, advancing the inserter through the cervix and into the uterus, and retracting a slider on the handle to release the intrauterine system

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

More Information on Dosage
Strength Dosage Availability
52MG INTRAUTERINE DEVICE;INTRAUTERINE Prescription

9. Drug name - NATAZIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071577 BAYER HLTHCARE Multi-phase contraceptive preparation based on a natural estrogen May, 2026

(3 years from now)

US8153616 BAYER HLTHCARE Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same Jan, 2028

(5 years from now)

Drugs and Companies using DIENOGEST; ESTRADIOL VALERATE ingredient

Treatment: Prevention of pregnancy; Treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
N/A,2MG,3MG,N/A,N/A;3MG,2MG,2MG,1MG,N/A TABLET;ORAL Prescription

10. Drug name - NEXAVAR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8877933 BAYER HLTHCARE Thermodynamically stable form of a tosylate salt
Dec, 2027

(5 years from now)

CN101065360B BAYER HLTHCARE Bay43-9006 Toluene Sulfonate Of Thermodynamically Stable Form
Sep, 2025

(2 years from now)

CN101065360A BAYER HLTHCARE Thermodynamics Stabilizing Form Of Bay43-9006 Toluenesulfonate
Sep, 2025

(2 years from now)

EP1797038B1 BAYER HLTHCARE Thermodynamically Stable Form Of Bay 43-9006 Tosylate
Sep, 2025

(2 years from now)

EP1797038A1 BAYER HLTHCARE Thermodynamically Stable Form Of Bay 43-9006 Tosylate
Sep, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618141 BAYER HLTHCARE Aryl ureas with angiogenesis inhibiting activity Feb, 2023

(4 months from now)

US9737488 BAYER HLTHCARE Pharmaceutical composition for the treatment of cancer Sep, 2028

(5 years from now)

Drugs and Companies using SORAFENIB TOSYLATE ingredient

Treatment: Treatment of advanced renal cell carcinoma; Treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment; treatment of advanced renal cell carcinoma; treatment of unresectable hepatocellular carcinoma

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription

11. Drug name - SAFYRAL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617597 BAYER HLTHCARE Pharmaceutical composition containing a tetrahydrofolic acid Feb, 2030

(7 years from now)

More Information on Dosage
Strength Dosage Availability
3MG,N/A;0.03MG,N/A;0.451MG,0.451MG TABLET;ORAL Prescription

12. Drug name - SKYLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7252839 BAYER HLTHCARE Delivery system and a manufacturing process of a delivery system Nov, 2023

(1 year, 1 month from now)

US9615965 BAYER HLTHCARE Inserter Sep, 2029

(6 years from now)

US10561524 BAYER HLTHCARE Inserter Sep, 2029

(6 years from now)

US10987244 BAYER HLTHCARE Inserter Apr, 2031

(8 years from now)

US9668912 BAYER HLTHCARE Inserter Apr, 2031

(8 years from now)

Drugs and Companies using LEVONORGESTREL ingredient

Treatment: A method of positioning an intrauterine system by holding an inserter handle with one hand, advancing the inserter through the cervix and into the uterus, and retracting a slider on the handle to release the intrauterine system; A method of positioning an intrauterine system (ius) by determining a depth of the uterus, holding an inserter handle with one hand, inserting the ius into the uterus, and retracting a slider on the handle to release the ius into the uterus

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

More Information on Dosage
Strength Dosage Availability
13.5MG INTRAUTERINE DEVICE;INTRAUTERINE Prescription

13. Drug name - STAXYN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8613950 BAYER HLTHCARE Pharmaceutical forms with improved pharmacokinetic properties Dec, 2028

(6 years from now)

Drugs and Companies using VARDENAFIL HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET, ORALLY DISINTEGRATING;ORAL Prescription

14. Drug name - STIVARGA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7351834 BAYER HLTHCARE ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Jun, 2022

(3 months ago)

US8637553 BAYER HLTHCARE Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
Feb, 2031

(8 years from now)

US9957232 BAYER HLTHCARE 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate
Jul, 2032

(9 years from now)

CN101257903A BAYER HLTHCARE Combination Therapy Comprising A Diaryl Urea Compound And A Pi3, Akt Kinase Or Mtor Inhibitors (Rapamycins) For Cancer Treatment
Mar, 2011

(11 years ago)

CN100522934C BAYER HLTHCARE Acardite As Raf Kinase Inhibitors With Omega-Carboxy Aryl Substituted
Jan, 2020

(2 years ago)

CN1721397A BAYER HLTHCARE For -Carboxy Aryl Substituted Diphenyl Urea As Raf Kinase Inhibitors
Jan, 2020

(2 years ago)

CN1219764C BAYER HLTHCARE For -Carboxy Aryl Substituted Diphenyl Urea As Raf Kinase Inhibitors
Jan, 2020

(2 years ago)

CN1341098A BAYER HLTHCARE For -Carboxy Aryl Substituted Diphenyl Urea As Raf Kinase Inhibitors
Jan, 2020

(2 years ago)

CN102816113B BAYER HLTHCARE Fluorin Generation [Omega]-Carboxylic Aryl Ureas For Treating And Preventing Symptoms And Disease
Jul, 2024

(1 year, 9 months from now)

CN1856469B BAYER HLTHCARE [Omega]-Carboxylic Aryl Phenylurea For The Treatment And Prevention Of Diseases And Disease Symptoms
Jul, 2024

(1 year, 9 months from now)

CN102816113A BAYER HLTHCARE Fluoro Omega-Carboxyaryl Diphenyl Urea For Treating And Preventing Disease And Disease Symptom
Jul, 2024

(1 year, 9 months from now)

CN1856469A BAYER HLTHCARE For The Treatment And Prevention Of Diseases And Disease Symptoms- Carboxylic Aryl Ureas
Jul, 2024

(1 year, 9 months from now)

CN101547903A BAYER HLTHCARE 4-[4-({[4-Chloro-3-(Trifluoromethyl)Phenyl)]Carbamoyl}Amino)-3-Fluorophenoxy]-N-Methylpyridine-2-Carboxamide Monohydrate
Sep, 2027

(4 years from now)

CN101547903B BAYER HLTHCARE 4-[4-({[4-Chloro-3-(Trifluoromethyl)Phenyl)]Carbamoyl}Amino)-3-Fluorophenoxy]-N-Methylpyridine-2-Carboxamide Monohydrate
Sep, 2027

(4 years from now)

IN215758B BAYER HLTHCARE Carboxyaryl Substituted Diphenyl Ureas
Jan, 2020

(2 years ago)

IN200100799P3 BAYER HLTHCARE Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
Jan, 2020

(2 years ago)

IN200600402P1 BAYER HLTHCARE Fluoro Substituted Omega-Carboxyaryl Diphenyl Urea For The Treatment And Prevention Of Diseases And Conditions
Jul, 2024

(1 year, 9 months from now)

IN240207B BAYER HLTHCARE A Fluoro Substituted Omega-Carboxyaryl Diphenyl Urea Compound Or A Salt, An Isolated Stereoisomer Thereof
Jul, 2024

(1 year, 9 months from now)

EP1690853A1 BAYER HLTHCARE Use Of Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
Jan, 2020

(2 years ago)

EP1690853B1 BAYER HLTHCARE Use Of Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
Jan, 2020

(2 years ago)

EP2298311B1 BAYER HLTHCARE W-Carboxy Aryl Substituted Diphenyl Ureas As P38 Kinase Inhibitors
Jan, 2020

(2 years ago)

EP1158985B1 BAYER HLTHCARE Omega-Carboxy Aryl Substituted Diphenyl Ureas As P38 Kinase Inhibitors
Jan, 2020

(2 years ago)

EP1158985A1 BAYER HLTHCARE Omega-Carboxy Aryl Substituted Diphenyl Ureas As P38 Kinase Inhibitors
Jan, 2020

(2 years ago)

EP1158985A4 BAYER HLTHCARE Omega-Carboxy Aryl Substituted Diphenyl Ureas As P38 Kinase Inhibitors
Jan, 2020

(2 years ago)

EP2298311A1 BAYER HLTHCARE W-Carboxy Aryl Substituted Diphenyl Ureas As P38 Kinase Inhibitors
Jan, 2020

(2 years ago)

EP1140840B1 BAYER HLTHCARE -G(V)-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
Jul, 2021

(1 year, 2 months ago)

EP1140840A1 BAYER HLTHCARE -G(V)-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
Jul, 2021

(1 year, 2 months ago)

EP1140840A4 BAYER HLTHCARE -G(V)-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
Jul, 2021

(1 year, 2 months ago)

EP1379507A1 BAYER HLTHCARE Heteroaryl Ureas Containing Nitrogen Hetero-Atoms As P38 Kinase Inhibitors
Apr, 2022

(5 months ago)

EP1379507B1 BAYER HLTHCARE Heteroaryl Ureas Containing Nitrogen Hetero-Atoms As P38 Kinase Inhibitors
Apr, 2022

(5 months ago)

EP2097381B1 BAYER HLTHCARE 4-[4-({[4-Chloro-3-(Trifluoromethyl)Phenyl)]Carbamoyl}Amino)-3-Fluorophenoxy]-N-Methylpyridine-2-Carboxamide Monohydrate
Sep, 2027

(4 years from now)

EP2097381A1 BAYER HLTHCARE 4-[4-({[4-Chloro-3-(Trifluoromethyl)Phenyl)]Carbamoyl}Amino)-3-Fluorophenoxy]-N-Methylpyridine-2-Carboxamide Monohydrate
Sep, 2027

(4 years from now)

EP1663978B1 BAYER HLTHCARE Fluoro Substituted Omega-Carboxyaryl Diphenyl Urea For The Treatment And Prevention Of Diseases And Conditions
Aug, 2028

(5 years from now)

EP1663978A2 BAYER HLTHCARE Fluoro Substituted Omega-Carboxyaryl Diphenyl Urea For The Treatment And Prevention Of Diseases And Conditions
Aug, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8680124 BAYER HLTHCARE Treatment of cancers with acquired resistance to kit inhibitors Jun, 2030

(7 years from now)

US9458107 BAYER HLTHCARE Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorphenoxy-N-ethylpyridie-carboxamide, its salts and monohydrate Apr, 2031

(8 years from now)

Drugs and Companies using REGORAFENIB ingredient

Treatment: Treatment of patients with gastrointestinal stromal tumor (gist), including but not limited to patients previously treated with imatinib and patients with gist having resistance to a kit tyrosine kinase inhibitor

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
40MG TABLET;ORAL Prescription

15. Drug name - VITRAKVI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9127013 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Oct, 2029

(7 years from now)

US8513263 BAYER HLTHCARE Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
Dec, 2029

(7 years from now)

US10172861 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Nov, 2035

(13 years from now)

US10799505 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Aug, 2036

(13 years from now)

CN103509017B BAYER HLTHCARE Substituted Pyrazoles As Trk Kinase Inhibitors [1, 5-A] Pyrimidine Compounds
Oct, 2029

(7 years from now)

CN102264736A BAYER HLTHCARE Substituted Pyrazole [1, 5-A] Pyrimidine Compound As Trk Kinase Inhibitor
Oct, 2029

(7 years from now)

CN102264736B BAYER HLTHCARE Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

CN103509017A BAYER HLTHCARE As Trk Kinase Inhibitor Substituted Pyrazole And [1, 5-A] Pyrimidine Compound
Oct, 2029

(7 years from now)

CN107428760A BAYER HLTHCARE (S) -N-[5 - [(R) -2-(2, 5-Difluorophenyl) - Pyrrolidin - -1 - Yl) - Pyrazolo [1-A] Pyrimidin - -3 - Yl)--3 - Hydroxy-Pyrrolidine - -1 - Crystal Of Amide Hydrogen Sulphate Salt
Nov, 2035

(13 years from now)

CN107428760B BAYER HLTHCARE (S) -N-(5 - ((R) -2-(2, 5-Difluorophenyl) - Pyrrolidin-1-Yl) - Pyrazolo [1, 5-A] Pyrimidine - -3 - Yl)--3 - Hydroxy-Pyrrolidine-1-Carboxamido Hydrogen Sulphate Crystal Form
Nov, 2035

(13 years from now)

EP3372605B1 BAYER HLTHCARE Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP2725028A1 BAYER HLTHCARE Substituted Pyrazolo[1,5-]Pyrimidine Compounds As Intermediates In The Synthesis Of Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP2725028B1 BAYER HLTHCARE Substituted Pyrazolo[1,5-]Pyrimidine Compounds As Intermediates In The Synthesis Of Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP2350071B1 BAYER HLTHCARE Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP2350071A1 BAYER HLTHCARE Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP3372605A1 BAYER HLTHCARE Substituted Pyrazolo[1,5-A]Pyrimidine Compounds As Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP3106463B3 BAYER HLTHCARE Pyrazolo[1,5-]Pyrimidine Compound As Trk Kinase Inhibitor
Oct, 2029

(7 years from now)

EP3106463A1 BAYER HLTHCARE Substituted Pyrazolo[1,5-]Pyrimidine Compounds As Trk Kinase Inhibitors
Oct, 2029

(7 years from now)

EP3106463B1 BAYER HLTHCARE Pyrazolo[1,5-]Pyrimidine Compound As Trk Kinase Inhibitor
Oct, 2029

(7 years from now)

EP3218380A1 BAYER HLTHCARE Preparation Of A Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate
Nov, 2035

(13 years from now)

EP3218380B1 BAYER HLTHCARE Preparation Of A Crystalline Form Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-Carboxamide Hydrogen Sulfate
Nov, 2035

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9676783 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds Oct, 2029

(7 years from now)

US10005783 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds Oct, 2029

(7 years from now)

US10047097 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds Oct, 2029

(7 years from now)

US9447104 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds Oct, 2029

(7 years from now)

US8865698 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds Oct, 2029

(7 years from now)

US10774085 BAYER HLTHCARE Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds Oct, 2029

(7 years from now)

US9782414 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate Nov, 2035

(13 years from now)

US10285993 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate Nov, 2035

(13 years from now)

US10813936 BAYER HLTHCARE Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate Nov, 2035

(13 years from now)

Drugs and Companies using LAROTRECTINIB SULFATE ingredient

Treatment: Method of treating cancerous solid tumors; Method of treating neuroblastoma, glioma, thyroid, and breast cancer solid tumors that exhibit an ntrk gene fusion; Method of treating solid tumors that exhibit an ntrk gene fusion after surgical resection; Method of treating solid tumors that exhibit an ntrk gene fusion; Method of treating solid tumors that exhibit an ntrk gene fusion in a pediatric patient; Method of treating lung cancer, undifferentiated sarcoma, or colorectal cancer that exhibits an ntrk gene fusion

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE CAPSULE;ORAL Prescription
EQ 100MG BASE CAPSULE;ORAL Prescription

16. Drug name - XOFIGO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6635234 BAYER HLTHCARE Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning Nov, 2022

(a month from now)

Drugs and Companies using RADIUM RA-223 DICHLORIDE ingredient

Treatment: Therapeutic treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
162mCi/6ML (27mCi/ML) SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.